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Genetic Transformation of the Lyme Disease Agent Borrelia
burgdorferi with Coumarin-Resistant gyrB
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No useful method to genetically manipulate Borrelia burgdorferi, the causative agent of Lyme disease, has
been developed previously. We have used resistance to the coumarin antibiotic coumermycin Al, an inhibitor
of DNA gyrase, as a genetic marker to monitor the transformation of B. burgdorferi by electroporation.
Introduction of site-directed mutations into the gyrB gene demonstrated that transformation was successful,
provided evidence that homologous recombination occurs on the chromosome, and established that mutations
at Arg-133 ofDNA gyrase B confer coumermycin Al resistance in B. burgdorferi. The coumermycin Al-resistant
gyrB marker and genetic transformation can now be applied toward dissecting the physiology and pathogenesis
of the Lyme disease agent on a molecular genetic level.
Lyme disease is 'the most common arthropod-borne infec-
tion in the United States, with almost 10,000 cases diagnosed
annually (2, 40). Borrelia burgdorferi, a bacterium in the
spirochete phylum, is the causative agent of Lyme disease in
North America (5, 6, 22, 41). The B. burgdorferi genome is
atypical for a bacterium: it is composed of both linear and
circular DNA molecules (3, 4, 7, 11, 15, 18, 38). The lack of a
system to genetically manipulate B. burgdorferi has frustrated
attempts to study its biology and pathogenesis. We have shown
that treatment of B. burgdorferi with the coumarin antibiotic
coumermycin Al inhibits bacterial growth and relaxes circular
plasmids (33). Coumermycin Al is an inhibitor of the bacterial
type II DNA topoisomerase DNA gyrase, which catalyzes the
introduction of negative supercoiling into DNA molecules (14,
16, 25, 29, 45). DNA gyrase is a tetramer composed of two A
subunits and two B subunits (16, 29); the latter are the target
of the coumarin drugs (1, 17, 25, 26, 39, 42).
Recently, we have isolated spontaneous mutants of B.
burgdorferi that are resistant to coumermycin Al (36). These
represent the only B. burgdorferi mutants resistant to an
antimicrobial agent that are currently available. In fact, only a
few B. burgdorferi mutants of any kind have been obtained by
selection (8, 9, 31, 32). We found single point mutations in
gyrB, the gene encoding the B subunit of DNA gyrase, in the
coumermycin A1-resistant mutants (36). These mutations
change a conserved arginine residue, Arg-133, to Gly or Ile.
This residue corresponds to Arg-136 in the Escherichia coli
DNA gyrase B protein and Arg-137 in the Haloferax sp.
protein, which are mutated to Leu, His, Cys, or Ser in
coumarin-resistant strains (10, 12, 19, 25). In the present study,
we have used coumermycin Al resistance as a genetic marker
to select for DNA introduced into B. burgdorferi. This now
provides a genetic system, previously unavailable, for studying
fundamental processes of pathogenesis in Lyme disease.
* Corresponding author. Phone: (406) 363-9224. Fax: (406) 363-
9204. Electronic mail address: ssamuels@rml.niaid.nih.gov.
t Present address: Department of Biochemistry, Vanderbilt Univer-
sity, Nashville, TN 37232.
MATERIALS AND METHODS
Bacteria and antibiotics. High-passage wild-type B. burgdor-
feri B31 (ATCC 35210) and the coumermycin Al-resistant
derivative CR1OE (36) were grown at 320C in Barbour-Stoen-
net-Kelly (BSK) II medium without gelatin. Coumermycin Al
and ciprofloxacin were obtained from Sigma and Miles, respec-
tively. Stock solutions were 50 mg of coumermycin A1 per ml
of dimethyl sulfoxide and 25 mg of ciprofloxacin per ml of
water and were stored at -20'C for less than 6 months.
Bacterial growth was assayed by A600 and reported relative to
growth in the absence of antibiotics as described previously
(33, 36).
Electroporation and selection. Five hundred milliliters of a
log-phase culture of B. burgdorferi B31 (-3 X 107 to 7 X 107
cells per ml) was pelleted in a GSA rotor (Sorvall) at 5,000 rpm
(4,000 X g) for 20 min at 40C, washed twice with 60 ml of cold
phosphate-buffered saline (PBS; Dulbecco's PBS without di-
valent cations), pelleted in an SS34 rotor (Sorvall) at 5,000 rpm
(3,000 X g) for 10 min at 40C, washed three times with 20 ml
of cold EPS (272 mM sucrose, 15% glycerol) pelleted in a
TMA3 rotor (Tomy) at 5,000 rpm (2000 X g) for 10 min at 40C,
and resuspended with 0.6 ml of cold EPS (final volume of -0.9
ml). Fifty microliters of cell suspension was mixed with 0.3 to
1 pLg of either total DNA partially digested with Sau3A or a
PCR product (in 1 to 5 pA of water) on ice and transferred to
a 0.2-cm electroporation cuvette (BTX) at 40C. One pulse was
delivered from a Gene Pulser with Pulse Controller (Bio-Rad)
set at 2.5 kV, 25 pF, and 200 fQ, producing a time constant of
4 to 5 ms (13). One milliliter of BSK II medium was immedi-
ately added to the cuvette, and the cells were transferred to a
15-ml culture tube with an additional 9 ml of BSK II medium.
Cultures were incubated at 320C for 24 to 48 h in the absence
of coumermycin A1. Then 0.1 ml of culture was plated in solid
BSK II medium with 0.1 pLg of coumermycin A, per ml as
described previously (23, 36) except that 100-mm-diameter
dishes were used with 15 ml of bottom agarose and 20 ml of top
agarose. The remaining 9.9 ml of culture was pelleted in a
TMA3 rotor at 10,000 rpm (4,000 X g) for 10 min, resuspended
in 1 ml of supernatant fraction, and plated. Plates were
incubated for 14 days at 320C in a humidified 5% CO2
atmosphere.
DNA and site-directed mutations. An 840-bp region of the
gyrB gene that encodes the first 280 amino acids of the
6045
6046 SAMUELS ET AL.
A B31-WT
(AGAGAT)
CR1OE-I
(ATrGAT)
CRIOE-D
(ATAGAC) B B31 111-3
A TG C A TGC
11D-3 CR1QE
ATG(C ATirCm
FIG. 1. Introduction of site-directed mutations into B. burgdorferi, using coumermycin A1 resistance as a selectable marker. (A) Coumermycin
Al-resistant transformants were selected in solid BSK II medium containing 0.1 jig of coumermycin A1 per ml. The following 840-bpgyrB PCR
fragments were used for electroporation. B31-WT encodes Arg-133, and CR1OE-I as well as CR1OE-D encode Ile-133 and contain site-directed
mutations. In CR1OE-I, the Arg-133 codon (AGA) was changed to ATT (Ile-133). In CR1OE-D, the Arg-133 codon (AGA) was changed to ATA
(Ile-133) and the Asp-134 codon (GAT) was silently changed to GAC (Asp-134). Plates were photographed with dark-field illumination. (B)
Sequence from gyrB of coumermycin Al-resistant transformants containing site-directed mutations. Ten transformants of each mutant were picked
from plates and grown under selection. Partial sequences are shown from wild-type B31, one representative transformant from the electroporation
with CR1OE-I (11I-3) as well as one from the electroporation with CR1OE-D (11D-3), and the spontaneous coumermycin Al-resistant mutant
CR1OE.
amino-terminal domain, which include Arg-133, was amplified
by PCR from wild-type B31 or coumermycin A1-resistant
CR1OE, using cloned Pfi polymerase (Stratagene) in a PTC-
100 Programmable Thermal Controller (MJ Research) with
primers iF (5'-ATGAATIATGTTGCTAGTAACATT-3')
and 840R (5'-AACATGAGTTCCCCCTTCTCTTGT-3') (20,
28, 34). The PCR program was 1 cycle of 94°C for 1 min, 25
cycles of 92°C for 30 s, 50°C for 30 s, and 72°C for 1 min, and
1 cycle of 72°C for 5 min; 1 ,ul (1%) of reaction product was
reamplified in a second PCR, in order to increase yield and
decrease total cellular DNA, and purified by using Wizard
PCR Preps (Promega). Arg-133 in strain B31 (34) corresponds
to Arg-138 in B. burgdorferi 212 (GenBank accession number
L14948 [28]). Site-directed mutations were introduced by
amplifying the 840-bp fragment in two pieces. The CR1OE-I
mutant gyrB was created by using iF and 411R/398A399A
(5'-AA'1T'11 CCATCAATATTAACATAAAC-3') as prim-
ers for the 5' portion and 385F/398T399T (5'-G'IT'ATGT
TAATATTGATGGAAAAATT-3') and 840R as primers for
the 3' portion. The amplification products were purified,
diluted to 30 ng per reaction, and assembled by using a
two-step amplification that included thermal cycling in the
absence (2 cycles) and then presence (25 cycles) of primers IF
and 840R. The CR1OE-D mutation was created as described
above except that 414R/398A402G (5'-AAAAATTTI'TCCGT
CTATATTAACATA-3') and 388F/398T402C (5'-TATGTTA
ATATAGACGGAAAAATEITT -3') were used as primers
instead of 411R/398A399A and 385F/398T399T, respectively.
DNA was isolated, amplified by PCR, and sequenced as
described previously (36).
Agarose gel electrophoresis and Southern. blotting. DNA
was isolated in liquid or in agarose plugs as described previ-
ously (35). DNA. in liquid was digested with restriction en-
zymes (ClaI and PvuII from Boehringer Mannheim Bio-
chemica and EcoRI from Life Technologies) and fractionated
by conventional 0.8% agarose gel electrophoresis in Tris-
acetate-EDTA. Molecular weight standards were lambda
DNA-HindIII digests (New England Biolabs). DNA isolated in
agarose plugs was fractionated by electrophoresis in 1% aga-
rose gels (FMC SeaKem GTG) by clamped homogeneous
electric fields (Bio-Rad CHEF Mapper) in 0.5X TBE (44 mM
Tris, 44 mM borate, 1 mM EDTA) at 6 V/cm, 120'C, for 18:19
h (run time calibration of 2.0) with temperature set at 12'C
(actual run temperature of - 14C) and switch times from 0.18
s to 1:13.19 min (determined by CHEF Mapper XA interactive
software for separation of DNA between 5 and 1,000 kb with
a ramping constant of -1.1 in Molecular Biology Agarose).
Gels were vacuum blotted (VacuGene XL; Pharmacia LKB) to
Hybond-N (Amersham), with two depurination and two dena-
turation steps instead of extended steps (24), and UV cross-
linked (Stratalinker; Stratagene). The membranes were probed
in QuikHyb (Stratagene) at 680C in a hybridization oven
(Autoblot; Bellco) with the 840-bp gyrB PCR fragment ampli-
fied in two sequential reactions and labeled with [a-32P]ATP
by random priming (Boehringer Mannheim Biochemica). The
blots were washed twice for 15 min at 240C in 2x SSC (0.3 M
NaCl and 30mM sodium citrate)-0.1% sodium dodecyl sulfate
(SDS), washed once for 30 min at 60'C in 0.2X SSC-0.1%
SDS, and exposed to Hyperfilm-MP (Amersham).
RESULTS
Genetic transformation with total DNA. Electroporation,
the application of high-voltage electric pulses to effect genetic
transformation, has been successfully used with a large number
of bacterial species (44), including the spirochete Serputina
hyodysenteriae (43). Therefore, DNA from wild-type B. burg-
dorferi B31 and the isogenic coumermycin Al-resistant mutant
CR1OE, in which Arg-133 of DNA gyrase B is mutated to Ile,
were isolated and partially digested with Sau3A. The resulting
DNA fragments were electroporated into wild-type B31 in nine
separate experiments. Total DNA from B31 cells, a negative
control, yielded a mean of 0.1 coumermycin A1-resistant
colony per ,ug of DNA (standard error [SE] 0.1), which
represents the background level of spontaneous mutations
(.10-8). Total DNA from CR1OE cells yielded a mean of 12
colonies per ,ug of DNA (SE 3). The means of these two
treatments differ significantly (P = 0.0003 as determined by a
J. BACTIERIOL.
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FIG. 2. Susceptibility of coumermycin Al-resistant transformants
of B. burgdorferi to growth inhibition by coumermycin Al (A) and
ciprofloxacin (B). Wild-type B31, coumermycin Al-resistant CR1OE,
and transformants 11I-3 and 11D-3 were grown in BSK II medium
containing various concentrations of antibiotics. Growth in the absence
of antibiotics was defined as 100% relative growth. Error bars repre-
sent standard errors of the means derived from at least three indepen-
dent experiments.
Mann-Whitney U test, a nonparametric ranked analysis of
variance [37]). Intact (undigested) total DNA from CR1OE
yielded no transformants in our experiments.
Genetic transformation with a portion of the gyrB gene. We
used PCR to amplify the part of the gyrB gene that contains the
mutation site from wild-type and coumermycin A1-resistant B.
burgdorferi to use as substrates for electroporation. In 11
experiments, the wild-type 840-bp gyrB fragment produced a
mean of 2.2 coumermycin Al-resistant colonies per jig of DNA
(SE 1.3), and the 840-bp gyrB fragment encoding Ile-133
produced a mean of 220 colonies per ttg of DNA (SE 100). In
spite of the large variation in transformation efficiency among
experiments, which appears to be due to the physiological state
of the Borrelia cells, the difference between the two DNA
sources was statistically significant (P 5 0.0001 by a Mann-
Whitney U test). Under optimal transformation conditions,
which are reported in Materials and Methods, about i03
colonies per [ig of DNA (840-bp gyrB fragment encoding
Ile-133) are routinely obtained. PCR products of various sizes,
from 291 to 1,905 bp (the entire gyrB gene [34]), have been
successfully used to transform B. burgdorferi. Preliminary elec-
troporation results indicate that DNA molecules of about
1,000 bp transform most efficiently.
To confirm that transformation of B. burgdorferi was due to
introducing exogenous DNA and not to generating spontane-
ous mutations, as well as to localize the recombination event to
within the gyrB gene, we created site-directed mutations in the
gyrB gene both at and adjacent to the codon for Arg-133. These
synthetic mutations silently changed the codon for Ile-133
from ATA to ATT (CR1OE-I) or the codon for Asp-134 from
GAT to GAC (CR1OE-D). Mutant gyrB gene fragments were
electroporated into wild-type B. burgdorferi cells with a trans-
formation efficiency of about 1,000 coumermycin A1-resistant
colonies per [ig of DNA (Fig. 1A). Ten transformants from
each electroporation experiment were isolated, and their gyrB
genes were partially sequenced. All 20 of the transformants
tested contained the site-directed mutations at Ile-133 or
Asp-134 (Fig. 1B).
Characterization of coumermycin Al-resistant transfor-
mants. The transformants were indistinguishable in gross
morphology (by dark-field microscopy) and protein content
(by SDS-polyacrylamide gel electrophoresis and Coomassie
brilliant blue staining) from either wild-type B31 or the
spontaneous coumermycin A1-resistant mutant CR1OE (data
not shown). The transformants had levels of resistance to
coumermycin A1, the selective agent, similar to that of the
spontaneous mutant (Fig. 2A). To determine if the coumer-
mycin A1 resistance in the transformants was a result of a
factor that conferred a general resistance to antibiotics, we
assayed for the ability of ciprofloxacin to inhibit the growth of
B. burgdorferi cells. Ciprofloxacin is a potent antimicrobial
agent that targets the A subunit of DNA gyrase and whose
mechanism of action is different from that of coumermycin A1
(14, 33, 45). The transformants were no different from B31 and
CR1OE in ciprofloxacin susceptibility (Fig. 2B), suggesting that
transformation of the Arg-133-to-Ile mutation specifically con-
ferred resistance to coumermycin A1.
The gyrB gene is located in the central region of the linear
chromosome of B. burgdorferi (7, 27). The copy number of the
gyrB gene in the transformants was determined by restriction
enzyme digestion and Southern blotting. Digestion with ClaI,
EcoRI, and PvuII produced single major bands of about 16,
8.6, and 20 kb, respectively, that hybridized to a PCR-gener-
ated 840-bp gyrB probe (Fig. 3A), indicating that there is only
a single gyrB gene per genome equivalent. A minor hybridizing
band of about 4.4 kb was produced by EcoRI digestion; the
identity of this band is unknown, but it may be the result of
hybridization to the parE homolog (20). The gyrB gene was
mapped to the chromosome in CR1OE and the transformants
by pulsed-field gel electrophoresis and Southern blotting (Fig.
3B).
DISCUSSION
Taken together, the results presented here strongly suggest
that genetic transformation of B. burgdorferi by electroporation
is feasible and that the introduced DNA can recombine into a
homologous site on the chromosome. This is the first demon-
stration of a useful genetic exchange system in any species of
the genus Borrelia. Therefore, molecular tools are now avail-
able for defining virulence factors and understanding the
pathogenic mechanisms used by B. burgdoferi to cause Lyme
disease. In addition, transformation provides an assay for the
VOL. 176, 1994
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FIG. 3. Mapping of the gyrB gene in coumermycin Al-resistant transformants of B. burgdorferi. DNA from wild-type B31, coumermycin
Al-resistant CR1OE, and transformants 11I-3 and 11D-3 was digested with ClaI, EcoRI, or PvuII and fractionated by conventional gel
electrophoresis (A) or fractionated intact by pulsed-field gel electrophoresis (B), Southern blotted, and hybridized with a gyrB probe.
ability of mutations to confer coumermycin A1 resistance, and
these results provide evidence that the Arg-133-to-Ile mutation
actually confers drug resistance in B. burgdorferi. These exper-
iments also indicate that B. burgdorfen has a homologous
recombination system, consistent with previous findings (30).
Twentyfold more transformants per jig of DNA were gener-
ated by using the amplification product (the 840-bp gyrB
fragment) than with total (partially digested) DNA. However,
on a molar basis, total DNA resulted in at least 80 times more
transformants than the amplification product. This effect,
although modest, may be due to a restriction-modification
system in B. burgdorferi, consistent with the report of methyl-
ated adenine residues in some strains (although not in B31)
(21).
The transformation efficiency is low (<103 transformants
per pug of DNA), probably because of the requirement for
homologous recombination as well as DNA entry. A further
explanation is that only a subpopulation of spirochetes are
either susceptible to transformation (perhaps because of a
difference in membrane or surface components) or able to
undergo homologous recombination. This hypothesis is cur-
rently difficult to assess because of the dearth of other clearly
defined genetic markers for B. burgdorferi. We are currently
assaying other mutations in gyrB for the capacity to confer
coumermycin A, resistance (34), and we are attempting to
construct broad-host-range plasmids with coumermycin A1-
resistant gyrB as a selectable marker for use as shuttle vectors.
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